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Introduction

Article 23 of European Union (Eu) Directive 86/609/EEC required that Mem
ber States promote the development and validation of alternative technologies
and stated that the European Commission ( Ec) "shall report before the end of
1987 on the possibility of modifying tests and guidelines" (European Parliament,
1986, Article 23). This Directive was replaced by Directive 2010/63/EU on the pro
tection of animals used for scientific purposes, which now requires thatMember
States develop and validate alternative approaches much more precisely and
specifies that the ultimate objective is the "full replacement of procedures on live
animals for scientific and educational purposes, as soon as it is scientifically pos
sible to do so" (European Parliament, 2010, Recital 10). However, having followed
theinitiativesofMemberStatesformorethan 3oyears, we see that developments
to replace animal experiments occur more by accident than by design. Direc
tive 2010/63/EU has not changed this either. This chapter explores the reasons
why the development and approval of animal-free methods are not advancing
more quickly, and why the numbers of animals used is not declining despite the
development of new methods. Undoubtedly, there are complex, multifactorial
reasons behind this. Our analysis leads us to the heart of the matter. There is no
master plan and there are no responsible project managers who effectively pur
sue the objectives of Directive 2010/63/EU at a national or EU level.
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In 2015, we started collating individual measures in order to tackle the prob
lems we encounter in our day-to-day work as an animal rights organization,
defining five categories (or pillars). We were encouraged to pursue our ideas
by developments in the United States through concepts, such as Toxicology in
the 21st Century-A Vision and a Strategy ( Tox21) (Krewski et al., 2010), as well
as by the EU ban on the marketing of cosmetics tested on animals, which came
into force in 2013. During this time, the Netherlands National Committee for
the protection of animals used for scientific purposes (NCad) presented its
plan, Transition to Non-Animal Research, referred to here as the NCad report
(NCad, 2016a), becoming the first EU member state to present a road map for
phasing out animal procedures and stimulating innovation without laboratory
animals. Unfortunately, no EU Member State, so far, has publicly spoken out in
favor of the Dutch initiative. On the contrary, its timeline has been criticized as
being unrealistic, risking the safety of medical treatment, and hampering basic
research. Only the government of the Brussels-Capital Region has put forward
a plan to phase out animal experiments along the lines of the NCad report.
Member States should show more support for such initiatives, which aspire to
achieve the goal of full replacement stated in Directive 2010/63/EU. At the EU
level, unfortunately, there is neither an overall strategy for phasing out the use
of animals for scientific purposes nor for monitoring the implementation of
the paradigm shift. It is important that changes take place, but how they take
place is subject to debate.
Writing from the point of view of a German animal rights organization, the
main focus of this chapter is Germany. Although Germany claims to be espe
cially committed to developing animal-free methods, it ranks among the high
est in terms of animal experiments in the EU, together with France and the
United Kingdom.

1

Part 1: How Seriously Do Member States Take the Tasks and
Obligations Stated in Directive 2010/63/EU?

A master plan to end animal experiments requires suitable resources for effec
tively reducing animal experiments and increasing market-ready animal-free
methods. In the following we discuss steps towards that final goal.
On 1 December 2016, the Netherlands became the first EU Member State
to present a road map for "phasing out animal procedures and the promo
tion of innovation without laboratory animals" (NCad, 2016a, p. 3). They are
convinced that some uses of animals-currently required by law for safety
testing of chemicals, food additives, pesticides, and (veterinary) medicines as

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:0BPM
via free access

90

BAUMGARTL-SIMONS AND HOHENSEE

well as the commercial launch of biological products (e.g., vaccines)-can be
phased out by 2025, while maintaining existing safety levels. However, their
road map recommends that regulatory pre-clinical tests for the registration
of new biological substances/products not be phased out by 2025 because
there is a lack of replacement methods. Similarly, animal experiments in
the field of "curiosity-driven" (NCad, 2016a, p. 38) basic research is not to be
terminated by 2025 because there is a basic right to freedom of research;
and, as no one knows the subject of research in advance, animal experi
ments cannot be easily replaced with new animal-free methods. Therefore,
it has been necessary to implement 10-year plans for each individual area
of research. In the case of animal experiments in applied and translational
research (implementation of preclinical research in clinical development),
which are also not to be phased out by 2025, the development of replace
ment methods is to be accelerated. The aim is to reduce significantly the use
of laboratory animals for education and training. The planning encompasses
transition objectives, transition strategy, and management of the transition.
There is every indication that the NCad report, commissioned by the former
Minister for Agriculture, Martijn van Dam, has laid out solid project plan
ning with the goal of effecting system change from animal use to animal-free
procedures.
This type of planning should have been initiated at an EU-wide level in
2013 when Directive 2010/63/EU came into effect, requiring the phasing out
of animal procedures and the acceleration of innovation without laborato
ry animals. While no Member State has publicly spoken out in favor of the
Dutch initiative, the German research association, Deutsche Forschungsge
meinschaft (DFG) and the Allianz der Wissenschaftsorganisationen (Alli
ance of Science and Research Organizations) issued a critical assessment of
the plan, calling its timeline unrealistic and claiming it would endanger the
safety of medical treatment and hamper basic research (BfR, 2017a). Accord
ing to our organization (People for Animal Rights Germany-Federal Asso
ciation against Vivisection), a good master plan has the following attributes:
it includes all stakeholders, including the scientific community, industry, and
animal rights/welfare organizations; it has robust monitoring to assess the
paradigm shift towards animal-free science; and it has an active commitment
of all stakeholders to implement the plan. The master plan for an end to ani
mal experiments requires suitable resources that purposefully pursue this end
by reducing animal experiments and increasing market-ready animal-free
methods.
The master plan's foundation rests on five pillars:
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Pillar 1: Increased Research Fundingfor Animal-free Methods Is
Necessary
Here we refer to animal-free research in the field of applied and basic research.
This research field includes methods that can replace animal testing in regu
latory animal tests (in a narrow sense). The budget for animal-free research
methods should be drastically increased, with the EU and its Member States
implementing their own funding programs for replacement methods. Ger
many, for example, is not a suitable role model: at present, "system-changing"
replacement methods compete with "system-maintaining" refinement
and reduction methods, because the three options are funded by the same
programs.
The EU needs to increase the budget for funding animal-free research. In the
current funding period, only one program that is dedicated to replacement,
EU-ToxRisk, is funded. This European collaborative project is funded by
the EU Framework Program for Research and Innovation, Horizon 2020. The
project started on January 11 2016 and will last for six years. It currently has
only €30 million at its disposal (EU-ToxRisk, 2016), with 39 participating
groups. By comparison, during the last funding period, the EU Seventh Frame
work Program provided the project cluster, SEURAT-I, with €50 million in
funding for work towards the replacement of in vivo systemic dose-toxicity
testing (which ran until December 2016)-much more than the current
funding.
Special funding programs are essential for creating ready-for-series tech
nologies, i.e., mass production in large amounts with a lower product prize;
for example, the characteristics and viability of current cell systems must be
improved to recreate the functions of the natural organ as accurately as pos
sible; current organoid biotechnology needs to replicate the behavior of organs
more closely; and the functions of the capillary system and immune system
still need to be modeled.
National and European budgets, especially for validation studies, are
also necessary and the Eu Reference Laboratory for Alternatives to Animal
Testing-European Centre for the Validation of Alternative Methods (EURL
ECVAM) (EURL ECVAM, 2017a) should be provided with adequate resources.
This demands a great deal of work. Validation and qualification of the new in
vitro systems have been discussed in several workshops across the us. These
workshops were hosted by the Anlerican Institute for Medical and Biologi
cal Engineering (AIMBE) and the National Institutes of Health (NIH) at the
NIH campus in Bethesda, Maryland. Representatives of the EURL ECVAM
and of some European start-ups also took part. The participants determined
1.1
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the need for a broader definition of validation for the integration of new
platform technologies into preclinical safety evaluation. The new in vitro
systems, such as the chip technologies (cell and tissue platforms, microelec
trode systems with connected measuring devices), biomarkers, and the qual
ity of cell and tissue types derived from human stem cells were also seen as
needing evaluation in terms of safety for preclinical applications and ef
ficacy. The pharmaceutical industry, which is the primary customer of the
new multi-organ on a chip systems, should also be more involved (AIMBE,
2013).
The EU Member States need to support the concept of To.x21, developed in
the us (Krewski et al., 2010). The concept's goal is to provide a new basis for risk
and safety assessments of substances and products (i.e., regulatory toxicology),
using new techniques that are human-specific; and to promote the use of ani
mal tests only in exceptional cases (see also the Integrated Approaches to Test
ing and Assessment adopted by the Organization for Economic Cooperation
and Development, OECD, 2017). The OECD now includes 35 countries around
the world, across North and South America, Europe, and Asia.
A research focus is also needed on the implementation of cell culture media
ready for practical application and for which no animals suffer, i.e., without the
use of fetal bovine serum (see Redmond, 2018, in this Volume). Researchers in
the us have been able to work with serum-free media in a defined system since
1995 (Schaffner et al., 1995).
1.2

Pillar 2: Animal-free Methods in Teaching and Scientifi-c Research
Have to Be Expanded
The goal of Pillar 2 is to establish academic chairs-with corresponding per
sonnel and financial resources for research and teaching and regular profes
sorships-for animal-free research methods, courses of study in the life sci
ences that do not use animals, a broad range of papers not based on the use of
animals, and an increased number of theses and higher qualifications, with a
focus on animal-free methods.
In Germany, for example, individual chairs in some federal states or Bundes
liinder (Baden-Wiirttemberg, Berlin, Hesse, and North Rhine-Westphalia) have
been established to develop methods to replace animal use. Researchers are
thus able to offer students a perspective to get closer to the topic and to pre
pare their theses with non-animal methods. However, there are still only a few
chairs in some federal states. There is need for courses of study that address
scientific questions using new animal-free methods. So far, students in life
sciences courses, such as biology or human medicine, must, with few excep
tions, participate in courses that use animals. Furthermore, where platforms
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for alternatives to animal tests have been set up, the scientists involved usu
ally investigate 3Rs methods (replacement, reduction, and refinement), which
means that the scarce resources are spread across all three areas. Instead, the
platforms' financial resources need to be exclusively available for replacement
methods.
The situation is similar in other European Countries. There are a few na
tional centers for alternatives to animal use, such as, the Finnish Centre for
Alternative Methods, which teaches only animal-free replacement methods.
In the private sector, Altertox Academy (formerly the Center for Alternatives
to Animal Testing Academy) offers training for young scientists in replace
ment methods. Others national centers, such as the Danish 3Rs-Center, the
Swedish Toxicology Science Research Center, or the Romanian Center for Al
ternative Test Methods, were founded to implement the mission of Directive
2010/63/EU and teach not only the replacement of animal use but also reduc
tion and refinement. The range of programs of study for animal-free methods
(full replacement) should be expanded. It should be possible to choose courses
of studies at European universities that will enable students to do research and
develop methods without using animals.
1.3

Pillar 3: Bans on Animal Testing Must Be Consolidated and
Expanded
Since its review in November 2017, Article 58 of Directive 2010/63/EU has bare
ly led to sufficient improvements for laboratory animals. In the next review, the
EC must take into account any progress made in the field of alternative meth
ods that may lead to an end to the use of animals, in particular non-human
primates. The first step should be to repeal Article 55 of Directive 2010/63/EU,
which allows Member States to provide exceptions from the regulations pro
tecting non-human primates (European Parliament, 2010); it also allows ex
ceptions from Article 21 which stipulates that procedures not be performed on
animals if they involve severe pain, suffering, or distress. Therefore, with the
approval of the EC, Member States may, for example, use monkeys in experi
ments that involve severe pain, suffering, or distress.
Further bans should be introduced, including: a ban on patenting geneti
cally altered animals; and a full ban on animal tests for household products
and their components, including banning the sale of such goods (analogous to
the existing provisions for cosmetic products) is essential.
Viable European and national competency centers should be established,
with the following tasks: creating transparency for the public, monitoring ad
herence to EU animal welfare law, and setting up information offices for all
stakeholders.
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Closer cooperation/collaboration with scientists and agencies in the us,
which is more advanced in technological development. The us regulatory
authorities are also not hesitant to search for and accept new animal-free
methods. Even pharmaceutical and chemical companies think that the EC
should be more orientated towards American models, such as the Food and
Drug Administration (FDA) and the Environmental Protection Agency (EPA)
(Ettel, 2018). Another example is the new Interagency Coordinating Commit
tee on the Validation of Alternative Methods plan (National Toxicology Pro
gram, 2018).
1.3.1
Suggestions for Implementing Existing EU Law
The EC Department, Directorate-General for Environment, should have a Eu
ropean competency center, for monitoring adherence to EU law and provid
ing up-to-date information on pain, suffering/distress, and fear as well as on
animal-free testing methods and other information relevant to this range of
topics.
These additional tasks could also be integrated into existing structures, such
as EURL ECVAM's EU Network of Laboratories for the Validation of Alterna
tive Methods (EU-NETVAL), under the umbrella of the EC Directorate-General
for Environment. So far, EU-NETVAL comprises laboratories in individual EU
Member States that conduct validation studies and assess the reliability and
relevance of new animal-free methods (EU-NETVAL, 2018). The European vali
dation authority, EURL ECVAM, could also focus on transparency for the pub
lic, provide information offices for all stakeholders, and monitor adherence to
EU animal welfare law. It is also vital that a negative list be introduced that will
stand up in court, defining tests that may no longer be conducted for ethical
reasons.
The establishment of national competency centers as central institutions
for informing and educating all stakeholders involved is also necessary. At a
national level, these tasks could be completed by the EU National Committees
in the Member States. The national information structures established thus far,
in accordance with Article 49 of Directive 2010/63/EU, have laid the founda
tion for such tasks.
The competency centers would be responsible for developing lists of criteria
for assessing whether applications for animal experiments fulfill legal require
ments, criteria that are lacking, thus far, but are necessary. This requires prac
ticable assessment criteria for qualifying/quantifying the necessity, benefits,
and ethical justifiability of the animal procedure as well as specifying the level
of distress. The competency centers should also offer education schemes for all
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stakeholders. To this end, it would be necessary to develop content and perfor
mance records. We recommend developing an education scheme for animal
free testing methods, analogous to the courses of the Federation for Laboratory
Animal Science Associations (FELASA, n.d.).
Practical, user-friendly databases should be set up to allow reliable and
uncomplicated referencing of animal-free methods.
The approving authorities and monitoring agencies in the Member States
should be provided with adequate finances, expertise, and staff.
Steps must be taken to ensure that the Member States implement the re
quirements set out in Directive 2010/63/EU, without exception. In Germany, for
example, although stipulated by Directive 2010/63/EU, the approving authori
ties currently do not have a comprehensive right for evaluation when assessing
applications for animal procedures, due to a decision made by the Higher Ad
ministrative Court Bremen (Oberverwaltungsgericht Bremen, 2012). Directive
2010/63/EU stipulates that project evaluation should consist of six evaluation
points (European Parliament, 2010, Article 38, Section 2, Subsections a-f). It
should include an evaluation of the project objectives, the predicted scientific
benefits or educational value, and the severity of the procedures, and a harm
benefit analysis of whether the suffering, pain, and distress inflicted on the ani
mals is justified by the expected outcome, in light of ethical considerations and
the ultimate benefit to human beings, animals, or the environment.
1-4

Pillar 4: Success Monitoring of the Increase of Animal-free
Methods and the Reduction of Animal Experiments Is of Particular
Importance
This pillar is especially important. It stands for the need for quality manage
ment, as it entails control measures that systematically document the progress
of the paradigm shift. Unlike the other pillars, there are no approaches, as yet,
to achieve this goal; they have to be established from the start. Definitive pa
rameters should be determined for quantifying and qualifying the reduction of
animal experiments and the increase in animal-free methods. A retrospective
assessment for all animal tests conducted and the publication of their data
crucial. Directive 2010/63/EU expressly provides for such a retrospective as
sessment (European Parliament, 2010, Article 39).
Pillar 5: Complementary Measures Are Necessary
Complementary measures comprise drastically shortening the time needed
for assessing and approving animal-free research methods; researching ani
mal experiment models in order to de-validate them; and introducing a class
1.5
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action suit for animal welfare in the E U and its Member States, as well as pro
viding adequate resources for law enforcement authorities.
Moving from the development of an animal-free method to its implemen
tation in the regulatory framework, which would lead to a broader range of
applications, has taken too long. Periods of 12 to 15 years, or even longer, have
been a matter of course (Hartung, 2015). There is a lack of financial support
for proof-of-concept studies as well as pre-validation and validation studies, so
that developers spend a great deal of time seeking financial support. In addi
tion, regulatory authorities become involved in this process at too late a stage
(Hohensee and Bruning, 2016; Schoffl et al., 2000).
According to NC ad and other researchers, there is a "growing focus on Syn
thesis of Evidence", the experimental design and critical reviewing of exist
ing animal models (Cronin, 2017, p. 39; NCad, 2016a; Varga et al., 2010). Just as
the new animal-free methods must be validated, it is also necessary for animal
testing to undergo systematic review.
Greater demand for national and international coordination of the promo
tion and acceleration of validation, regulatory acceptance, and implementation
of animal-free methods (NCad, 2016a).

2

Part 2: How Has the Change of Course Been Pursued So Far
Nationally, in the E U, and Internationally?

Directive 63/2010/EU provides for a long-term withdrawal from all animal
experiments. Nevertheless, for many researchers, the development of
replacement methods has not been the priority it should be. It still has a niche
existence. Although some research groups focus on replacement, research and
budgets at both the national and European levels are too low and should be
embedded in a higher-level context. Here, more efforts are necessary.
2.1
Setting up Committees in Accordance with Directive 2010/63/EU
With Directive 2010/63/EU, the E U and its Member States have set the long
term goal of ending animal experimentation and promoting the development
of replacement methods for animal experiments. The Directive must be enact
ed in national law by all Member States. The amended German Animal Welfare
Act (Tierschutzgesetz) took effect in July 2013, and the new Animal Welfare Lab
oratory Animal Regulation (Tierschutz-Versuchstierverordnung) took effect in
August 2013. However, while opportunities for achieving a higher level of ani
mal protection should have been put in place, they were forfeited. Although
the necessary legal basis exists in primary law, a maximum limit for pain or suf
fering in animal experiments, and a ban on increasing animal experiments, by
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eliminating the exemption clauses, were not enforced in German law (Peters
and Stucki, 2012). Furthermore, the comprehensive right of project evaluation
pursuant to Article 36 of Directive 2010/63/EU was not implemented and was,
instead, replaced by a qualified plausibility check (Hildermann, 2015).
Article 49 of Directive 2010/63/EU states that all EU Member States must
establish National Committees for the protection of animals used for scien
tific purposes (European Parliament, 2010). In Germany, this role is performed
by the Federal Institute of Risk Assessment (Bffi), which has established the
German Centre for the Protection of Laboratory Animals (Bf3R), located at
the Bffi, as set out in the amendment of the German Animal Welfare Act that
took effect on July 13, 2013 (Bffi, 2017b ). According to Paragraph 45 of the Ger
man Animal Welfare Laboratory Animal Regulation, the National Committee
advises the competent authorities and animal welfare committees on matters
regarding the acquisition, breeding, accommodation, or care of vertebrates
and cephalopods ( as defined in Paragraph 11 Section 1 of the Regulation); or the
use of vertebrates and cephalopods in animal experiments. The National Com
mittee also advises the competent authorities, in accordance with Paragraph
46 of the Regulation, on matters regarding alternatives to animal experiments
(Bundesministerium fur Justiz und Verbraucherschutz, 2017).
The German Centre for the Protection of Laboratory Animals (Bf3R) was
founded in the context of the animal welfare initiative ("Tierwohlinitiative")
of the German Federal Ministry of Food and Agriculture (BMEL ) in 2015.
While before the establishment of the Bf3R, the Centre for Documentation
and Evaluation of Alternatives to Animal Experiments ( z EBET ) was of central
importance, it has now been integrated into the Bf3R as one of five areas of
competence. The competence areas are research and development of meth
ods to reduce pain and suffering of laboratory animals (refinement); the Na
tional Committee; development of alternatives in the field of toxicology; and
coordination of research funding. The last two areas of competence were
formerly tasks of Z EBET. However, the tasks of all competence areas are pre
dominantly performed by Experimental Toxicology and Z EBET (Bffi, 2017b).
Therefore, alternative methods are investigated, developed, and validated in
accordance with the 3R principles. Thereby, the focus has shifted from the de
velopment of replacement methods for animal experiments towards the 3Rs.
Today, refinement and reduction of animal use is treated of, at least, equivalent
importance.
2.2
Has Funding Been Increased in Recent Years?
2.2.1
Funding on a National Level (Germany)
Although an increasing number of projects are funded on a national level, those
who conduct research in replacement methods criticize that disproportionate
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funding for animal experiments and an exaggerated perception of their im
portance has led to a decades-long neglect of the development of replacement
methods and a reticence to promote them actively (Baumgartl-Simons, 2017;
Leist, 2016).
2.3

Programsfor the Development ofAnimal-free Methods: The Funding
Has to Be Shared with Refinement Methods
In Germany, projects are funded mostly by the German Federal Ministry of
Education and Research (Bundesministerium fi.ir Bildung und Forschung,
BMBF ). BMBF, Bf3R, and the set Foundation together provide approximately
€5. 7 million per year in funding for research into the development of replace
ment and complementary methods for animal experiments based on the 3R
principles. A few German federal states have established funding programs of
their own, including Baden-Wiirttemberg, which provides €400,000 per year;
and Rhineland-Palatinate, €701 000 every two years (see Table 3.1). Some in
dividual projects, such as postgraduate programs, are funded by the German
research association, D F G ; however, this funding is not dedicated to the devel
opment of animal-free methods and, therefore, is not listed here.
Note: This table presents an overview, not an official empirical survey.
On a state level, in Germany, it seems that an expansion of research asso
ciations and professorial chairs has slowly begun. Some federal states have
established research associations or professorial chairs and are providing ini
tial funding for a finite period. For example, Baden-Wiirttemberg funds the Do
erenkamp-Zbinden Chair of in vitro Toxicology and Biomedicine/Alternatives
to Animal Experimentation with €200,000 to €400,000 annually. However,
most of this funding is combined with research for the 3 Rs as a whole, so fund
ing for replacement methods alone cannot be quantified. For example, Berlin
may soon take over the Berlin-Brandenburg research platform (BB3R), with
an integrated postgraduate program; and it plans to establish an institute for
alternatives to animal experiments, with €8.6 million, at the Charite Univer
sity School of Medicine Berlin (Der Regierende Biirgermeister-Senatskanzlei
Berlin, 2017). The current BMBF funding has expired and negotiations for fund
ing on a state level are currently in progress. In Frankfurt, a professorship for
pharmaceutical technology has been established, with 3R methods as its main
research focus. During the next five years, €200,000 will be made available to
be shared with another chair for refinement methods. Lower Saxony finances
the research initiative R2N-Replace and Reduce, with €4.5 million. North
Rhine-Westphalia is funding the Centrum fi.ir Ersatzmethoden zum Tierver
such (CERST-NRW), a center for replacement methods for animal experimen
tation, with €500,000 per year for a period of five years.
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TAB L E 3 . 1

Funding for the development of animal-free methods in Germany

A. Chairs and platforms
Federal state

Subject

Designation

BadenWiirttemberg

Chair

The Doerenkamp- 2 00,000Zbinden Chair
400,000 per
annum
of in-vitro
Toxicology and
Biomedicine

BadenWiirttemberg

Berlin

3Rs platform/
Research
Association

BerlinBrandenburg
research
platform BB3R
with integrated
graduate
education
Chair of
pharmaceutical
technology

Federal
Ministry of
Education
and Research

Hesse

Chair

Lower Saxony

Research
Association

North RhineWestphalia

Chair

R2N, replace
and reduce in
Lower Saxony;
replacement and
complementary
methods for
trend-setting
biomedical
research
Centrum fur
Ersatzmethoden
zumTierversuch

Amount (€)

92,000
( 2 0 1 4-2 0 1 6 ) ,

negotiations
at state level
to continue

Financed by

(B M B F )

Hesse/
Johanna
Quandt
Foundation
4.5 million (4 Lower Saxony
years)
200,000 per
annum (5
years)

500,000 per
annum

North RhineWestphalia

( C E RST-NRW)
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TABLE 3.1

B.

Funding for the development of animal-free methods in
Germany (cont. )

Project funding

Germany-wide Development,
proof-onconcept

BadenWiirttemberg

Rhineland
Palatine

Development,
proof-onconcept

Approaches
for the
development of
replacement and
complementary
methods for
animal use

5.7 million
per annum

Development of 400,000 per
replacement and annum
complementary
methods for
animal use
Development, Development of
70,000/24
proof-on-conceptreplacement and months
complementary
methods for animal
use

Federal
Ministry of
Education
and Research/
Federal
Institute
of Risk
Assessment/
set Foundation
BadenWiirttemberg

Rhineland
Palatine

Since 1981, the BMBF has funded 530 projects for the development of 3R meth
ods (BMBF, 2016). The annual budget totals €5 million (although applicants
for funding from this BMBF research budget, and for research prizes awarded
for the development of alternatives to animal experiments, include develop
ers of refinement methods for animal experiments, i.e. animal experimenters).
So far, more than €170 million in funding has been provided in this area (Ho
hensee and Bruning, 2016). However, a 2011 study published by the Fraunhofer
Institute for Systems and Innovation Research showed that about 30 per cent
of the projects funded between 1981 and 2000 focused on refinement (Hiising
et al., 2011). In addition, few institutions or projects receive sufficient funding.
For example, the BfR simultaneously supports about ten working groups for
up to three years, each with an average of €35,000 per year. By comparison, the
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development of the in vitro pyrogen test required €6 million from development
to implementation. The working group needed €400,000 per year (Thomas
Hartung, personal communication, August 2016). Numerous applicants com
pete for the low project funds. The funding amount of about €5.7 million from
the BMBF, set foundation, and Federal Institute of Risk Assessment is far too
small, with no budget available for pre-validation and validation studies. Since
the developers of refinement methods can also apply for these funds, even less
money is available. Funding for refinement methods should have its own bud
get. The half-hearted funding is intended to give the impression that Germany
actively supports the development of new animal-free methods. However, it is
not an expression of the decision to phase out animal experiments, instead, it
slows down the development.
Additional Programs
There are a few complementary funding programs to the main program,
Alternatives to Animal Experiments, such as e:Bio-Innovative Competition
Systems Biology, which runs until 2020. Systems biology unites complex high
throughput experiments with mathematical modeling of the obtained data,
to develop models to predict complex biological processes on cellular, tis
sue, and organ levels as well as in the entire organism (BMBF, 2011). One of
the complementary programs, BioOkonomie 2030-GO-Bio, aims to further
develop innovative research topics in the field of life sciences to the point
of making these available for economic implementation, like innovative
start-ups (Bundesministerium filr Wirtschaft und Energie, 2017). This is in
teresting for organ on a chip technology developments intended for market
launch.
2 .4

Funding Transregional/On a European Level
2.4.1
There are also a few programs financed by more than one EU Member State,
such as InnoSysTox-Innovative Systems Toxicology for Alternative to Animal
Testing, a €3 million project financed jointly by Germany and the Netherlands
(ZonMw, 2017). The application deadline was December 2014. Another pro
gram is the translational funding initiative, Multilateral Collaboration in
Computational Neuroscience: Germany-US-Israel-France (BMBF, 2015a).
The EU-wide budget is unknown. In Germany, €901 000 - €225,000 in fund
ing was available for a three-year term. The application deadline for the first
run was November 2016. However, as previously noted, across the EU there is
currently only one program financed by the Eu's funding framework Horizon
2020 dealing with animal-free issues, EU-ToxRisk, which deals with feasibility
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studies for methods that most urgently need to be developed in toxicology. In
EU-ToxRisk, 39 project participants must share a budget of €30 million.
The research guidelines that define what methods are most urgent are set
out by the scientists themselves, and not by the EC. This was the case with proj
ect cluster SEURAT-I (SEURAT-I, 2013), which received €25 million in funding
from both the EU and the industrial association, Cosmetics Europe. Cosmetics
Europe also contributes to the funding for EU-ToxRisk (amount unknown)
(Cosmetics Europe, 2017). Especially urgent areas of research should be stipu
lated, and the development of animal-free methods must have priority. At the
EU level, scientists seem to agree on the methods in most urgent need of de
velopment; but in Germany, there is no agency that decides which methods
need to be developed and provided with preferential funding. Apparently, a
particular bone of contention is whether it is better to fund all research in
discriminately, in the spirit of scientific freedom or originality, or to demand
specific research into solutions for important questions (Hohensee, 2015). In
the case of achieving the end goal of full replacement, as set out in Directive
2010/63/EU, the answer is clear: Research developments should not be funded
indiscriminately, but rather clear priorities are necessary, with replacement of
foremost importance.
2.4.2
Funding on an International Level
The us was the first country to take decisive steps towards ending animal ex
periments, with the concept Tox21 (National Center for Advancing Transla
tional Sciences, N CATS, 2017a). Toxz1 is a collaboration among the NIH, FDA,
EPA, and the National Toxicology Program at the National Institute of Environ
mental Health Sciences, with the goal of achieving better assessment of the
toxicity of substances by using faster and more efficient human-specific meth
ods in high-throughput technologies. To this end, fitfor-purp ose cell models
have been developed; and a high-throughput apparatus has been set up, which
scans the gene expressions in human cells for alterations after they have been
exposed to the test substance. The EPA has established its own National Cen
ter for Computational Toxicology, in which prediction models are developed
based on the new results (Committee on Toxicity Testing and Assessment of
Environmental Agents, 2007; N CATS, 2017b).
A number of organ on a chip start-ups, most of them from the us, have
been established to produce lab-scale prototypes. Zhang and Radisic (2017) de
scribed the most important 29 start-ups, dividing their work into groups: start
ups developing barrier functions, start-ups developing tissue-interface on a
chip, and start-ups developing parenchymal-tissue on a chip. The first scientist
to envision the possibility and pioneer the practice of quantitatively-simulating
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molecular and cellular biological systems, with in vitro devices was Profes
sor Michael L. Shuler of Cornell University, New York (Hurelcorp, 2018). To
gether with Professor James J. Hickman of the University of Central Florida,
Shuler founded the start-up, HESPER0 S, in 2014 (HESPERO S , 2017). Hickman
developed the first serum-free media for hippocampal neuron cultures in
1995 (Schaffner et al., 1995) and published the first readouts of electrical and
mechanical functions of neurons in 1998 (Ravenscroft et al., 1998). Together
with Shuler and others, Hickman integrated cardiac, muscle, neuronal, and liv
er modules in a microphysiological system, under continuous flow conditions
in a serum-free defined medium, utilizing a pump-free platform (Oleaga et al.,
2016). So far, HESPER0 S has successfully tested six organs on a chip (Miller,
2017).
TissUse, a German spin-off from the Technical University of Berlin, was
founded by Dr. Uwe Marx in 2010. The initial focus of this company was on
the development of two-organ and four-organ models. Today, like HE SPERO S,
their ultimate goal is to develop a human on a chip, integrating at least 10 or
gan-like tissue constructs of human origin. Instead of using a gravity-driven
flow, like Hesperos, the TissUse platform contains a built-in micropump, driv
en by an external pneumatic controller. A second microfluidic circuit ensures
drainage of the fluid excreted through a kidney's epithelial cell laye r. The four
organ chip with intestine, liver, skin, and kidney is already available and can
be co-cultured for up to 28 days (Maschmeyer et al., 2015). The Wyss Institute
for Biologically Inspired Engineering at Harvard University in Boston has pro
duced 19 university start-ups (Wyss Institute, 2018) and is known for its organ
on a chip developments. One of the current research results is a pulmonary
thrombosis model on a chip. The research was co-financed by the Defense Ad
vanced Research Projects Agency (DARPA), Janssen Pharmaceuticals (Jain et
al., 2018), and funding from NCATS (NCATS, 2018).
The Center for Alternatives to Animal Testing (CAAT) was founded in 1981 by
Alan Goldberg, a professor at Johns Hopkins University in Baltimore. CAAT was
then financed by the American Cosmetic Toiletry and Fragrance Association
(CTFA), which was interested in the development of replacement methods
for testing their products (CAAT, n.d. a). CAAT's goal is to create fundamental
knowledge regarding possible methods for replacing tests using whole organ
isms (i.e. living animals) with alternative methods in the development and
testing of commercial and therapeutic products. CAAT established its own
in vitro toxicology laboratory in 1985. In 1988, the cosmetics company, Avon,
financed the first program for replacing animal experiments in the field of con
tact allergies. Since 1989, CAAT has also been supported by government agen
cies and, as of 1992, by the EPA. CAAT-Europe, at the University of Konstanz in
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Germany, the European equivalent to CAAT in the us (CAAT-US ), was founded
in 2009. CAAT coordinates transatlantic relations between the us and Europe
in the field of animal-free methods, by bringing together international stake
holders in congresses and workshops on various topics of non-animal research
(Universitat Konstanz, 2018). On information days, the public is informed
about the latest developments in this field. Both CAAT-US and CAAT-Europe
in Germany train young scientists in new animal-free methods (CAAT, n.d. b).
Expanding education and research towards science without animal
experiments is crucial, as only a small group of researchers currently work on
replacement methods. Despite the aforementioned funded individual profes
sorial chairs, there is still no way of completing a course of studies that would
equip students with the professional capacity to develop alternatives to ani
mal experiments. In order to complete a thesis at one of the newly established
chairs (see above), the student must first have studied one of the more common
courses of studies, such as biology, medicine, veterinary medicine, biochemis
try, pharmaceutics, toxicology, or biophysics, which, for the most part, contin
ue to use animals for training ( SATI s, 2017a). Only very few tertiary institutions
allow the use of alternatives to animal dissection on ethical grounds. Instead,
tolerance towards alternatives to the use of animals in training courses has
decreased, depending on the course organizers' attitude. Only four German
State Higher Education Acts (North Rhine-Westphalia, Hesse, Saarland, and
Bremen) allow the right to decline using animals on ethical grounds (SATI S,
2017b). Most students quickly get used to using animals because they do not
want to belong to a fringe group, without prospects of gaining a professional
foothold, or they want to keep their options open. The lack of opportunities
for attaining qualifications in animal-free courses of studies leads to a lack of
qualified young scientists in the area of animal-free methods, so that fund
ing bodies sometimes argue that the reticence in providing finances results
from insufficient scientific standards (Hohensee, 2015). The lack of political
will means that the subject continues to go in circles.
The Time-consuming Validation Process
The time taken for the validation and approval of animal-free testing meth
ods urgently needs to be shortened. The broadening of funding by the BMBF
program, Alternatives to Animal Testing, to include strategies for imple
menting newly developed methods as replacements for animal experiments
(BMBF, 2015b, Module 11), is a first step in the right direction; but it is by no
means enough. Validation studies, in particular, are extremely expensive and
time-consuming and go through the bottleneck of the European validation
authority, EURL ECVAM, which has limited capacities. There are simply not
2 .5
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enough resources. If a validation study is successfully conducted, the process
of recommendation by EURL ECVAM begins with consultations with different
committees, including the Preliminary Assessment of Regulatory Relevance
(PARERE) and the EURL ECVAM Stakeholder Forum (ESTAF) (EURL ECVAM,
2017b). EURL ECVAM then consults with other EC committees, as well as the
other international partners for validation and cooperation on the develop
ment of alternative test methods. The general public and companies, who
would ultimately implement the development, are given time to submit com
ments. Only after a long period of time is a Test Guideline drafted, and the
method is then included in the annexes of the relevant statutory regulation.
This sometimes requires 10 years (Hohensee, 2016a). There are, however, in
stances where the inventor is not interested in validation because it would tie
up resources; for example, Ulrich Stock, who developed a borosilicate chamber
with a blood-like solution to test heart valves under human-like conditions in
2011 (personal communication, November 2011). Here an agency is needed to
oversee proceedings.

3

Part 3 : Why Are There Insufficient Animal-free Test Methods and in
Which Areas?

In Which Areas Are There Insufficient Animal-free Test Methods and
Why?
In this section, we focus on the field of toxicology alone. Relevant animal-free
methods in the field of toxicology could also be applied to other areas. There
has been great progress in the development of replacement methods in the
area of local toxicity testing (e.g., skin and eye tests), where many animal ex
periments have already been replaced (AltTox, 2016). However, there are still
no replacement methods for long-term studies of the organism as a whole, for
example, in the area of inhalation toxicity or tests for reproductive damage
and damage caused to offspring. The development of replacement methods
for testing environmental toxicity is also only rudimentary.
The goal of the holistic approach is to be able to depict the entire organism
in a simplified and miniaturized form. This is a complicated process because
individual organs, their biology, and their interactions within the body are
highly complex. In order to replace this complex organism in experiments, sci
entists aim to create a human on a chip, in which all the vital human organs
are combined on a chip of miniaturized scale of about 1:10,000. At present,
about eight miniaturized organs can be simulated and interconnected (Ingber,
2017). However, to construct a human surrogate for drug screening, scientists
3 .1
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are convinced that it will not be necessary to replicate a perfect human body
but simply to provide a better predictive model than animal models (Wang
et al., 2016 ) . For such simplified models, many different technical approaches
have been developed; for example, according to chip fabrication techniques,
medium composition, delivery systems of media, nutrients, oxygen, metabo
lites, and so forth, have a strong influence on the quality of cell or organ cul
tures and the results. Wang et al. (2016 ) provide an exploratory overview of
current developments in multi-organ systems and their pro and cons. Since
each start-up presently holds only a piece of the entire puzzle, the authors
recommend that the multiple companies should be motivated to join forces to
combine their techniques and patents, thereby fostering the continued evolu
tion of more advanced products. In many cases, the viability of organoid sys
tem cultures cannot, currently, be guaranteed for long-term investigations.
Depending on the laboratory, there are groups whose cell systems can be
utilized for just one week (Hohensee, 2017) and others for three months (Epit
helix, 2017 ). These differences may result from the organs' different needs and
the difficulties of recreating miniaturized human organs, especially in the case
of such vital organs as the liver or kidneys. Wang et al. (2016) discuss the need
for a common culture medium, with full chemical definition, as a blood sur
rogate that can maintain the viability and function of various organ models
and by the use of extracellular matrices can influence the reproducibility and
physiologically-realistic ratio of liquid to cell volumes in the (multi-) organ on
a chip system.
Methods in the field of inhalation toxicology are advanced with superficial
and deeper respiratory epithelium in vitro and with, in some cases, a viability
or usability of more than a month (Epithelix, 2017 ) . Lung models have been
in use for quite some time (Esch, Bahinski and Huh, 201s; Huh et al., 2010 ) .
One method, having achieved general approval, is currently undergoing a
validation study in Germany (Hoffmann et al., 2017 ) . However, it was initially
intended for replacing animal experiments in the area of acute toxicity. Devel
opments in the area of long-term toxicity are not as advanced and are being
explored in a feasibility study within the framework of the EU project cluster,
EU-ToxRisk (EU-ToxRisk, 2016 ).
Recreating a reproductive tract in a multifluidic system is a particular chal
lenge. Some advancements have already been made, such as the develop
ment of 3D cell culture models of animal Fallopian tubes, in which embryos
can even develop in the "tubular fluid" (Chen et al., 2017 ) . There are models
of the vagina and in vitro test systems with ectocervical cells and fibroblasts,
which have been developed to test substances for their irritant, toxic, or endo
crine disruptive effects (Ayehunie et al., 2016; Landry et al., 2016 ) . An artificial

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:0BPM
via free access

HOW CAN THE FINAL GOAL OF COMPLETELY REPLACING ANIMAL

107

reproductive cycle has also been created, using murine ovarian follicles in vi
tro, to investigate the mechanisms of reduced fertility (Zhu et al., 2016). First
steps have been taken to culture parts of female ovaries, using human follicles,
to study the maturation processes (Laronda et al., 2014). There are also initial
developments for studying the hormonal cycle, using human ovarian tissue as
well as mice and human follicles (Skory et al., 2015). More advanced is a system
(EVATAR) to simulate the 28-day hormone profile of the female reproductive
tract to study its influence on reproductive tissue (Xiao et al. 2017). However,
due to species differences between mice and humans, the use of murine tissue
can only be a first step. The goal is to construct models with human-specific
tissue material (for an overview see Eddie et al., 2015). A repro-on a chip could
be used in the future to recreate mechanistic developments and disorders in
the development of the reproductive organs in the field of basic and applied
research but not reproductive behavioral disorders or detrimental effects on
offspring. Other solutions would have to be found for these. The project cluster
EU-ToxRisk is also conducting feasibility studies in the field of developmen
tal and reproductive toxicology (EU-ToxRisk, 2016). Unfortunately, hormonal
regulation (feedback loops with hyp othalamus, adenohyp ophysis, and thyroid,
which affect the tissues) and immune defense, which would allow the modula
tion of a miniature human on a chip, are lacking.
What is appealing about this human on a chip technology is that automa
tion could rapidly shorten the time and cost of development by using large
rooms filled with robotic systems to simultaneously run tests on a multitude
of chips, with different concentrations of a variety of substances, without the
disruption of human factors (e.g., introduction of bacteria, measuring errors,
or pipetting errors). This would facilitate more targeted, cheaper, and faster
development and production and make it more attractive for industry.

Why Aren't Developments Progressing More Quickly in Germany ?
3 .2
The development of animal-free methods primarily depends on the advance
ment of knowledge (Linz School of Education, 1999; Schmiel, 2006) as well
as other factors, such as efficient methods of investigation and measurement,
high-performance research facilities with a workplace environment conducive
to creativity, innovative staff, and, most significantly, sufficient funds. The fol
lowing observations regarding these factors are restricted to Germany.
Powerful Methods of Investigation and Measurement
3.2.1
Modern molecular biological and biochemical methods, insights into cell cul
ture, stem cell research, chip technology, omics technologies, computers of
high performance, algorithms, potent imaging techniques, and bioprinters
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have considerably advanced the development of animal-free testing methods
(BMBF, 2016; D F G , 2017 ). While these powerful methods should also be available
to universities and other research facilities, they would involve considerable
cost. Several facilities are currently known to need money for 3D bioprinters in
order to advance research on non-animal replacements, including the Institute
of Veterinary Anatomy of the Free University Berlin. It is possible that some
research remains at a certain level of development due to lack of instruments.
This situation has been recognized by the German Research Foundation ( D F G ,
2017). The problem could be addressed by establishing decentralized method
centers, whose services would be available to all authorized research institutes.
Collaborations with extramural institutes (e.g., Fraunhofer Institutes) also
need to be facilitated and, perhaps, expanded.
3.2.2

High-performance Research Facilities with a Workplace
Environment Conducive to Creativity
In addition to up-to-date research topics, the workplace environment is also
important for the research staff, for example, in terms of hierarchy, recogni
tion, and interdisciplinary collaboration. Recent years have seen progress
in this regard. New university courses have also been introduced, some of
which are suitable for the development of replacement methods for animal
experiments, such as Medical Biotechnology (Technische Universitat Berlin,
TU-Berlin, 2017), Biomedical Computing (xStudy S E, 2017a), Life Science En
gineering (Hochschule fur Technik und Wirtschaft Berlin, HTW-Berlin, 2017),
Biomedical Engineering (xStudy S E, 2017b), and Biochemistry and Molecular
Biology (Universitat Bayreuth, 2018). There are increasingly more student ex
changes between international partner universities (xStudy S E, 2017a).
3.2.3
Innovative Staff
Understandably, aspiring students and postgraduates, among others, are in
fluenced by their career prospects when choosing suitable fields of study. This
choice involves assessing how much return they can actually get on their in
vestment in their course of studies. The best employees go to institutes with
the best reputations ("everyone wants to go to Harvard"); institutes that do the
best research, who are best known, that have significant influence in the sci
entific community, that are not economically threatened, and that pay their
staff well. For this reason, attractive degree courses in the area of animal-free
methods are needed (e.g., Medical Biotechnology at TU-Berlin). There should
also be a climate of internationality, enabling an exchange of know-how and
strategic thinking in problem solving. At present, there are professorial chairs
in Germany, where one can learn animal-free research and testing methods;

Kathrin Herrmann and Kimberley Jayne - 978-90-04-39119-2
Downloaded from Brill.com11/11/2019 09:57:0BPM
via free access

HOW CAN THE FINAL GOAL OF COMPLETELY REPLACING ANIMAL

109

however, entire courses of studies are not available. Students often must work
with animals or animal organs because they must first complete a standard
syllabus (e.g., biology), after which they can attend single courses or com
plete their theses at the newly installed chairs, in places such as Frankfurt,
Diisseldorf, and Konstanz (Buchmann Institute for Molecular Life Sciences,
2017; Hohensee; 2016b; University of Konstanz, 2018).
3.2-4
More Capital from the Corporate Sector Is Necessary
Sufficient capital is important. The development of animal-free test methods
in Germany is largely financed by state funding. This means that the risks in
volved with research and development are borne by society (taxpayers), whilst
the returns on successfully developed technologies benefit all stakeholders. It
would, therefore, make sense to provide not only national and European fund
ing but also more capital from the corporate sector. European organizations,
such as Cosmetics Europe and the European Partnership for Alternative Ap
proaches to Animal Testing (EPAA), are good examples (Cosmetics Europe,
2017; EPAA, 2017). Tax relief for companies that invest in research has been de
manded for many years and should be implemented (Verband der Chemischen
Industrie, 2017). In the us, there are more ambitious programs leading to bet
ter and more innovative scientific outputs. N CATS at N I H and DARPA recently
funded a us$150 million program for grants in the field of toxicity testing, drug
efficacy evaluation, and disease modeling (Wang et al., 2016). It seems that
there is a strong motivation to make the new systems successfully applicable.
In Europe, there are no such programs available. Funding programs are frag
mented into small individual measures with much smaller budgets. So far, only
the Netherlands has clearly expressed its intentions. Other Member States are
reserved, expressing themselves at best behind closed doors and referring to
their cooperation within the framework of their National Committees. Many
researchers who use animal methods likely have little interest in the success of
the Dutch plan. Such reservation by Member States could be a barrier towards
the success of the plan.

4

Part 4: The Netherlands Makes a Name for Itself

Why Is the NC ad Report a Good Templatefor a Paradigm Shift?
As of May 2017, NCad has published 108 documents, demonstrating its suc
cess (NCad, 2016a); however, the Netherland's former Minister of Agriculture,
Martijn van Dam, ambitiously pursued "the final goal of full replacement" as
set out in Recital 10 of Directive 2010/63/EU (European Parliament, 2010). The
4 .1
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manner in which Dutch politics has responded to the initiative is truly sen
sational. On April 8, 20161 the Dutch Minister of Agriculture requested that
NCad Chairman, Herman Koeter, develops a phase-out timeline for proce
dures involving animal use. The plan, Transition to Non-Animal Research, was
published on December 15, 2016 (NC ad, 2016a). The history of its development
is as interesting and groundbreaking as the plan itself.
The Development of the NCad Report
4.2
The NCad plan is not the result of a whim but rather the product of years
of expert preparation, in which all stakeholders were involved. In June 2014,
the Dutch Ministry of Economic Affairs commissioned the expert group, The
Think Tank on Supplementary Financing for Alternatives to Animal Testing
(De Denktank Aanfullende financierung alternatieven voor dierproeven), to
develop recommendations for additional funding for the development of "in
novations without laboratory animals" (NCad, 2016a, p. 42,). The Think Tank
presented its 140-page report, In Transition! The Netherlands leads the way in
laboratory animal-free innovations, in October 2015 (Henneman et al., 2015).
Based on this report, on April 8, 20161 the Minister of Agriculture, Martijn van
Dam, assigned NC ad the task of presenting a strategy for phasing out animal
procedures. Van Dam specified that the strategy should involve the National
Institute of Public Health and Environmental Protection (Rijksinstituut voor
Volksgezondheid en Milieu Netherlands, RIVM ). RIVM has significant exper
tise in toxicity testing and is both national and international coordinator for
3Rs methods. van Dam instructed NCad to name specific phasing-out targets
and stated that the legally required toxicity tests should be phased out within
10 years, which would reduce the number of animals used in experiments by
10% in the Netherlands. He also emphasized the goal, formulated in the Think
Tank's recommendations, that the Netherlands become the world leader in
laboratory animal-free innovations by 2025 (NCad, 2016b).
NCad conducted two expert workshops on June g and July 7 1 2016 in co
operation with the RIVM (NCad, 2016a, p. 13). In August 20161 the Linkedin
group, Towards a Future of Scientific Progress Without the Use of Experimental
Animals, was founded (Koeter, 2016). As of November 17, 2016, the group had
245 members, but unfortunately it delivered little of substance (NCad, 2016a,
p. 51). A public consultation was held on September 8, 2016 in Den Haag, where
a broad range of organizations commented on specific recommendations,
such as "It is possible to move away from the regulatory animal procedures
within the next ten years" (NC ad, 2016a, p. 51). The report, Transition to Non
Animal Research, was presented to van Dam and published on December 15,
2016.
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What Facts and Figures Are Named in the Phase- out Timetable?
4. 3
In its report, NCad divided animal experiments into different areas and as
sessed the possibility of reducing them by 2025. The Netherlands aims to be an
international leader in the field of innovation without laboratory animals by
2025 and sees a realistic chance of achieving this goal. Areas and possibilities
of reduction, as noted in the NCad report, are:
1.
Regulatory tests:
- "The use of laboratory safety testing for chemicals, food additives, pes
ticides, and (veterinary) medicines can be phased out by 2025 whilst
maintaining the existing safety level" (NCad, 2016a, pp. 3, 17).
- "The use of laboratory animals in regulatory tests for the release of
biological products, such as vaccines, will be phased out by 2025 whilst
maintaining the existing safety level" (NCad, 2016a, pp. 17-18).
- Regulatory preclinical tests associated with the registration of new
biological substances/products cannot be phased out by 2025. "At this
stage, however, due to the complex composition of these products and
generally complex mechanism of action, the regulatory preclinical
research associated with the registration of new biopharmaceuticals
(such as vaccines or monoclonal antibodies) cannot be phased out at
the same pace" (NCad, 2016a, pp. 17-18).
2.
Basic scientific and medical research:
- Animal experiments in the field of "curiosity-driven basic research
cannot be phased out by 2025. Therefore, individual ten-year plans are
necessary for each area of research" (NCad, 2016a, p. 15). The complex
procedures and interactions in an organism as a whole cannot be sim
ulated at the current time.
- "Within the field of fundamental scientific research, the reduction or
phasing out of the use of animals is not realistic in the short term in all
areas of research" (NCad, 2016a, p. 18).
Applied and translational research:
3.
- While animal experiments in applied and translational research (im
plementation of preclinical research in clinical development) cannot
be phased out by 2025, the development of replacement methods can
be accelerated. This includes investing more in human-specific mod
els and less in animal models. The Netherlands aims to become "an
international leader" in this respect (NCad, 2016a, p. 19).
Education and training:
4.
- "By focusing on animal-free practices and actively reflecting on the use
of laboratory animals in education, the use of laboratory animals for ed
ucation and training can be significantly reduced" (NC ad, 2016a, p. 19).
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Transition Objectives, Transition Strategy and Management of the
Transition
NCad has found that there is a realistic chance of completely phasing out
animal experiments in the areas of regulatory safety tests (for chemicals,
food additives, pesticides, and veterinary and human medical products) and
regulatory tests for the release of biological products (e.g., vaccines) by 2025.
This requires a transition strategy and management of the transition. The de
velopment will not take place on its own. Therefore, we strongly recommend
the development of NCad's transition objectives, transition strategy, and pro
gram for transition management.
4-4

Transition Objectives
44 1
The transition objectives refer to a paradigm shift away from existing mind
sets and practices, which are combined with animal use, to a strong focus on
innovations without laboratory animals. In regulatory research, this means a
significant reduction in the use of laboratory animals; in the field of basic re
search, the development of a ten-year vision for each area; and in the field of
applied and translational research, more rapid progress, for example, through
the development of human models for human diseases. Furthermore, the use
of animals in education and training can be significantly reduced (NC ad, 2016a,
pp. 3-4).
Transition Strategy
44 2
NC ad has stated that the following is necessary for a good transition strategy:
- the use of human data
- international cooperation for a new approach to risk assessment
- multidisciplinary cooperation on the development and approval of replacement methods
- monitoring of the evaluation and dissemination of replacement methods
- monitoring and evaluation of the reduction of animal procedures (since
the contribution replacement methods make towards the reduction of the
number of animals used in the Netherlands cannot currently be proven)
- development of an innovation index for replacement methods (data
warehouse, directory) in collaboration with other countries (NCad, 2016a,
p. 24).
Transition Management
44 3
The NCad report states that the key to success is (international) collaboration
among all stakeholders. The Minister for Agriculture would have the guiding
role but also involve other ministries. The existing Interdepartmental Working
Group on Alternatives to Animal Procedures would be transformed into an
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Interdepartmental Management Group, with the involvement of representa
tives from several ministries. The Management Group would draft an agenda
for the new replacement methods that need to be developed in consultation
with all stakeholders.

Evaluation and Conclusions
4. 5
An analysis of the 108 reports that led to the decisions presented in the NCad
report, showed that the phase-out timeline is not an unrealistic idea. The
phase-out timeline is based on the results of two years of intense consultation
and work, involving representatives of stakeholders from the fields of science,
applied research, contract research, laboratory animal science, medicine,
replacement of animal testing, and animal welfare (NCad, 2016c, p. 2). The
phase-out timeline was developed with all participating groups; as such, the
road map is certainly ambitious but by no means unrealistic. It is, therefore,
disconcerting that other EU Member States have either ignored or rejected the
Dutch plan, and none have expressed support.

5

The Way Forward

What has to be done to rigorously pursue the "phasing out of animal proce
dures and the stimulation of innovation without laboratory animals" (NCad,
2016a, p. 3)? With the NCad report, Transition to Non-Animal Research, the
Netherlands has not only presented an opinion but has developed a con
cept for purposefully affecting a paradigm shift. The NCad report contains
clear transition objectives, a transition strategy, and a program for transition
management. Our association, People for Animal Rights Germany, proposes
that the following can be achieved, based on the Dutch concept and includ
ing our five pillars and our demand for a master plan for phasing out animal
experiments:
The EU Member States' National Committees (European Parliament,
2010, Article 49) should endorse the NCad plan. The national responsible
ministers (especially the ministers responsible for the animal welfare,
science, and research portfolios) should advocate for the adoption of the
NC ad concept, to encourage the governments of the Member States to
implement the Dutch plan in their own countries. Parallel to this, we rec
ommend that the responsible national ministers vote in their respective
Councils of Ministers to support the NCad plan at an EU level.
Based on the national governmental resolutions and the resolutions of
the EU Council of Ministers, the EC should adopt the NC ad concept as a
principle for action for reducing animal testing and funding animal-free
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procedures. Political action is also urgently needed to stop the different
stakeholders working against each other.
These objectives can be achieved by the EU Members States' ministers
responsible for the animal welfare, science, and research portfolios, by
developing a new approach to assessing the risks posed by substances
and asserting this internationally beyond the EU. The pivotal issue is the
actual risk (risk assessment) and not the substances' overall hazard po
tential (hazard assessment) (NCad, 2016a, p. 20).
In the short term, the Netherlands intends to compile a priority list for
areas of regulatory testing that lack animal-free methods. Other EU
Member States should actively support the Netherlands in compiling this
list. The EU Member States and the EC should then approve funding pro
grams for these procedures. Funding programs should only be available
for animal-free testing methods and provide continuous funding, from
development to final validation.
It is necessary that the responsible ministers in the EU Member States
optimize the validation process. The results of methods to be validated
must be compared with human data and not with data from animal ex
periments (NCad, 2016a). The time needed for the validation process
should also be shortened.
The responsible ministers in the EU Member States should agree on the
introduction of a monitoring system for quality assurance during the
transition process, which would monitor the development and applica
tion of animal-free procedures and the phasing out of animal procedures,
allowing timely intervention in the case of negative developments.
The Dutch Minister of Economic Affairs will set up sub-domains in order
to draw up ten-year plans for the different areas of basic research. The
plans will name realistic objectives for "innovations without laboratory
animals" (NCad, 2016a, p. 3). This task is a particular challenge, as basic
research has, until now, been regarded as sacrosanct. This makes it all
the more important that all EU Member States actively participate in the
drawing up of these plans.

6

Final Remarks

We strongly recommend transforming the current plan, Transition to Non
Animal Research, proposed by NC ad, from an uncoordinated single process
to a targeted joint project, in which all stakeholders stand behind the same
goals and actively pursue them based on an overall plan. The NCad report de
scribes crucial objectives: ending animal procedures for regulatory tests; listing
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and prioritizing the animal-free procedures that need to be developed; and
drawing up ten-year plans for phasing out animal procedures in the different
areas of basic research. Under the leadership of politics, the principles that
underlie the NCad report should be implemented in the EU Member States,
supported by the EC, and ideally in step with international regulatory authori
ties and scientific bodies. The implementation should be ensured by national
and international project management, accompanied by a monitoring system,
and made transparent to the public. A joint pursuit of the Dutch concept by
the other EU Member States would work towards achieving the goal of Recital
10 of Directive 2010/63/EU to replace animals for scientific and educational
purposes. This requires a common will and joint preparation of individual
plans in European (or even international) workshops with all major stake
holders, in particular science, industry, and public authorities. The successful
phase out of animal testing in the field of cosmetics, which is gradually tak
ing place worldwide, as well as current multi-organ on a chip developments
across many countries, have shown that it is possible to achieve these goals
together.
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